Inogen — Third Quarter 2026 Earnings Summary

Financial Performance:

• No specific financial metrics (revenue, earnings, margins, cash flow, etc.) are disclosed in this press release; the release states that third-quarter financial results for the period ended September 30, 2026, will be announced separately.

Guidance and Future Outlook:

• The company anticipates a shift toward a more streamlined commercial model following the Rotech divestiture announced in September.
• Management aims to drive sustainable, profitable growth and expand access to respiratory solutions.
• Forward-looking statements indicate expectations regarding the impact of the transaction on revenue growth, margins, profitability, and the financial profile.
• The company expects to complete the Rotech transaction and classify the Rental Business as discontinued operations.

Business Segments and Product Lines:

• The company is executing a divestiture of Rotech, announced in September, to streamline its commercial model.
• The company continues to focus on its portfolio of innovative respiratory therapy devices for homecare settings used to treat chronic respiratory conditions.
• Management plans to sharpen focus on product commercialization and go-to-market strategies.

Market and Competitive Landscape:

• Inogen operates in the global medical technology market for homecare respiratory products, partnering with patients, prescribers, home medical equipment providers, and distributors.
• The company faces risks related to market adoption of portable oxygen concentrators and competition.

Risks and Challenges:

• Risks include the satisfaction of closing conditions for the Rotech transaction and the execution of patient transitions.
• Potential challenges involve accounting treatment of the transaction, the amount of net proceeds received, and the timing and amount of share repurchases.
• Operational risks include market acceptance of products, reimbursement changes, sales and distribution capabilities, and planned product development.

Management Commentary and Tone:

• The Board of Directors appointed Andy Reding as President and CEO, succeeding Kevin Smith, citing the need to improve performance to capture opportunities.
• Chairperson Elizabeth Mora stated that Reding brings proven experience in building high-performing teams and scaling complex medtech businesses.
• Reding expressed excitement about the company's mission, team strength, differentiated product portfolio, and deep customer relationships.
• The Board expressed gratitude to Kevin Smith for his role in broadening and expanding Inogen's reach.

Other Key Points:

• Andy Reding, previously Chief Operating Officer, has been appointed President and CEO and a member of the Board of Directors.
• Reding brings over 30 years of medical technology experience, including prior roles as Chief Commercial Officer of Viant Medical and Vice President/General Manager of Hillrom Respiratory Health.
• Reding played a central role in the Rotech divestiture.
• The company will host a conference call with investors and analysts at 5:00 p.m. ET to discuss the third-quarter results.
• The press release mentions an anticipated share repurchase program, though specific details on amounts or timing are not provided.